Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth S Borden

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Frontiers in Oncology|March 21, 2022
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and ValidationElizabeth S Borden, Kenneth H Buetow, Melissa A Wilson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 19, 2022
NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic NeoantigensElizabeth S Borden, Suhail Ghafoor, Kenneth H Buetow, et al.
HGG Advances|October 20, 2024
HCV- and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profilesElizabeth S Borden, Annika Jorgensen, Heini M Natri, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
HCV- and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profilesElizabeth S Borden, Annika Jorgensen, Heini M Natri, et al.
Frontiers in Immunology|December 19, 2019
Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic KeratosesElizabeth S Borden, Paul Kang, Heini M Natri, et al.
Journal of Pediatric Hematology/Oncology|December 8, 2025
Malignant Transformation of a Pediatric Intracranial Nongerminomatous Germ Cell Tumor to Embryonal Rhabdomyosarcoma: Case Report and Literature ReviewElizabeth S Borden, Ben Posorske, Clayton Long, et al.
Cancers|January 11, 2022
Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to MelanomaElizabeth S Borden, Anngela C Adams, Kenneth H Buetow, et al.
Cancers|May 14, 2022
High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint InhibitionAnngela C Adams, Elizabeth S Borden, Anne M Macy, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Distinct sets of molecular characteristics define tumor-rejecting neoantigensAnngela C Adams, Anne M Macy, Elizabeth S Borden, et al.
Plos Genetics|October 3, 2025
Towards a transcriptomic biomarker for the classification of melanocytic neoplasmsElizabeth S Borden, Colin T Hastings, Nithish Prakash, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Frontiers in Oncology|March 21, 2022
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and ValidationElizabeth S Borden, Kenneth H Buetow, Melissa A Wilson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 19, 2022
NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic NeoantigensElizabeth S Borden, Suhail Ghafoor, Kenneth H Buetow, et al.
HGG Advances|October 20, 2024
HCV- and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profilesElizabeth S Borden, Annika Jorgensen, Heini M Natri, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2024
HCV- and HBV-mediated liver cancer converge on similar transcriptomic landscapes and immune profilesElizabeth S Borden, Annika Jorgensen, Heini M Natri, et al.
Frontiers in Immunology|December 19, 2019
Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic KeratosesElizabeth S Borden, Paul Kang, Heini M Natri, et al.
Journal of Pediatric Hematology/Oncology|December 8, 2025
Malignant Transformation of a Pediatric Intracranial Nongerminomatous Germ Cell Tumor to Embryonal Rhabdomyosarcoma: Case Report and Literature ReviewElizabeth S Borden, Ben Posorske, Clayton Long, et al.
Cancers|January 11, 2022
Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to MelanomaElizabeth S Borden, Anngela C Adams, Kenneth H Buetow, et al.
Cancers|May 14, 2022
High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint InhibitionAnngela C Adams, Elizabeth S Borden, Anne M Macy, et al.
Biorxiv : the Preprint Server for Biology|February 26, 2024
Distinct sets of molecular characteristics define tumor-rejecting neoantigensAnngela C Adams, Anne M Macy, Elizabeth S Borden, et al.
Plos Genetics|October 3, 2025
Towards a transcriptomic biomarker for the classification of melanocytic neoplasmsElizabeth S Borden, Colin T Hastings, Nithish Prakash, et al.
Pageof 2